Research programme: GSG2 protein/CDK8 inhibitors - Selvita

Drug Profile

Research programme: GSG2 protein/CDK8 inhibitors - Selvita

Alternative Names: SEL 120; SEL120-34; SEL120-34A

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selvita
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 8 inhibitors; GSG2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Colorectal cancer; Haematological malignancies; Solid tumours

Most Recent Events

  • 06 Apr 2018 Selvita plans a phase I trial of SEL 120 for Acute myeloid leukaemia in first quarter of 2019
  • 06 Feb 2018 Preclinical trials in Haematological malignancies in Poland (PO), prior to February 2018
  • 06 Feb 2018 Preclinical trials in Solid tumours in Poland (PO), prior to February 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top